HomeTrialNCT05509790
🔬NCT05509790Phase 1ACTIVE NOT RECRUITING

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Study Summary

This is a study of LY3484356 in Chinese participants with advanced breast cancer. Participants must have breast cancer that is estrogen receptor positive (ER+), HER2 negative (HER2-). The purpose of this study is to measure how much LY3484356 gets into the bloodstream and how long it takes the body to remove it. The safety and effectiveness of LY3484356 will also be studied. Participation could last up to 28 months.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment17 participants
Primary Completion
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.866231+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.